<DOC>
	<DOC>NCT02430766</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Lymph Node Metastases.</brief_summary>
	<brief_title>Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)</brief_title>
	<detailed_description>By enrolling patients with unresectable Lymph Node Metastases adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Lymph Node Metastases.</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<criteria>Lymph Node Metastases diagnosed by positive biopsy or noninvasive criteria, Not suitable for surgical resection, Eastern Cooperative Oncology Group (ECOG) score of 01, A prothrombin time ratio &gt; 50%, Platelet count &gt; 80x10^9/L, Ability of patient to stop anticoagulant and antiplatelet therapy for seven days prior to and seven days post NanoKnife procedure, Able to comprehend and willing to sign the written informed consent form (ICF), Have a life expectancy of at least 3 months. Cardiac insufficiency, ongoing coronary artery disease or arrhythmia, Any active implanted device (eg Pacemaker), Women who are pregnant or women of childbearing potential who are not using an acceptable method of contraception, Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnifeâ„¢ LEDC System, Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>irreversible electroporation</keyword>
	<keyword>Unresectable Lymph Node Metastases</keyword>
</DOC>